Press release
The NF1-PN Market Size in 7MM to Witness Notable Growth, Expanding from USD 380 million in 2023 | DelveInsight
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics).
DelveInsight's report titled "Neurofibromatosis Type 1-associated Plexiform Neurofibromas (NF1-PN): Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/neurofibromatosis-type1-associated-plexiform-neurofibromas-nf-pn-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" offers comprehensive epidemiological data along with insights into market trends, an analysis of the competitive landscape, current and emerging therapeutic approaches, and assessments of the patient journey concerning NF1-PN, a rare disease.
The report forecasts that the NF1-PN market across the 7MM, which includes the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan, will grow from approximately USD 380 million in 2023 at a considerable CAGR by 2034. This anticipated growth is attributed to ongoing research into the genetic underpinnings of these tumors, the availability of medical therapy as an alternative to surgery, improvements in administration ease, and a decrease in side effect profiles of emerging therapies.
According to the report, the United States consistently holds the highest market share among the 7MM, with around USD 230 million in 2023.
The report provides a detailed epidemiological analysis and forecasts up to 2034, segmented by total NF1 diagnosed prevalent cases, diagnosed cases of NF1 manifestations, age-specific NF1-PN diagnosed cases, NF1-PN cases by clinical symptoms, and NF1-PN cases eligible for surgery in the 7MM. In 2023, the majority of diagnosed NF1-PN patients were estimated to be in the US, followed by Germany.
Current NF1-PN treatment practices, emerging drugs, market shares of individual therapies, and unmet medical needs from 2020 to 2034 are also addressed in the report. While surgery remains a standard treatment for many patients, it is often complex, not always feasible, carries inherent risks, and has a high possibility of tumor recurrence. A multidisciplinary approach involving genetics, neurology, radiology, and surgery, is vital for effectively managing the disease's physical and emotional impacts.
With an improved understanding of the genetic basis of plexiform neurofibromas, targeted therapies like the MEK inhibitor KOSELUGO (AstraZeneca and Merck) have emerged as promising options, especially for pediatric patients with inoperable NF1-PN. Building on this progress, researchers are exploring other MEK inhibitors for potential use in both pediatric and adult patients.
The current NF1-PN developmental pipeline includes additional MEK inhibitors such as Mirdametinib (SpringWorks Therapeutics), FCN-159 (Fosun Pharmaceutical), and PAS-004 (Pasithea Therapeutics). Another emerging drug, HLX-1502 (Healx), offers a unique investigational treatment option for NF1 patients. In October 2024, the US FDA granted Fast Track Designation (FTD) to HLX-1502 for the treatment of NF1.
Recent developments include findings for PAS-004, which demonstrated no dose-limiting toxicities in Phase 1 clinical trials. An external Safety Review Committee recommended proceeding with its higher doses without modification in February 2025, highlighting the potential of these emerging therapies to revolutionize NF1-PN treatment.
Although NF1-PN presents significant challenges due to its highly individualized treatment needs-including multidisciplinary teamwork, tumor regrowth, and complications arising from tumors developing in critical areas like the head, neck, chest, or spine-the emergence of novel therapies as an alternative to surgery, improving administration ease and minimize side effects, is expected to broaden treatment options and enhance market growth.
Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY OF NF1-PN
4. NF1-PN EPIDEMIOLOGY AND MARKET METHODOLOGY
5. NF1-PN MARKET OVERVIEW AT A GLANCE
6. KEY EVENTS
7. NF1-PN BACKGROUND AND OVERVIEW
8. EPIDEMIOLOGY AND NF1-PN PATIENT POPULATION
9. NF1-PN PATIENT JOURNEY
10. NF1-PN MARKETED DRUGS
11. NF1-PN EMERGING DRUGS
12. NF1-PN: SEVEN MAJOR MARKET ANALYSIS
13. NF1-PN UNMET NEEDS
14. NF1-PN MARKET SWOT ANALYSIS
15. KOL VIEWS
16. MARKET ACCESS AND REIMBURSEMENT
17. APPENDIX
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
Related Reports
Plexiform Neurofibroma Market Insight [https://www.delveinsight.com/report-store/plexiform-neurofibroma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Plexiform Neurofibroma Market Insight, Epidemiology And Market Forecast report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Plexiform Neurofibroma market trends, market drivers, market barriers, and key Plexiform Neurofibroma companies, including SpringWorks Therapeutics, Array BioPharma, Novartis, Shanghai Fosun Pharmaceutical Development Co, Ltd.,and Ashvattha Therapeutics, among others.
About DelveInsight
DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=the-nf1pn-market-size-in-7mm-to-witness-notable-growth-expanding-from-usd-380-million-in-2023-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The NF1-PN Market Size in 7MM to Witness Notable Growth, Expanding from USD 380 million in 2023 | DelveInsight here
News-ID: 4128581 • Views: …
More Releases from ABNewswire
Top Real Estate Selling Agent in Cedar City, UT, Lists Unique Property Featuring …
Cedar City, UT - A stunning 3-bedroom, 2.5-bathroom home at 1329 W 1600 S has hit the market, offering families the perfect blend of comfort and outdoor adventure. Built in 2006, this thoughtfully designed 1,690-square-foot property sits at the base of Cedar Mountain, providing residents with exceptional access to nature while maintaining modern living convenience.
The property's prime location near recreational opportunities makes it particularly attractive to active buyers, according to…
EDsmart.org Unveils "Triple A+ Colleges" - 23 Elite Institutions Recognized for …
EDsmart.org, a leading provider of college rankings and resources, has released its inaugural "Triple A+ Colleges" list, recognizing 23 institutions that demonstrate exceptional, well-rounded performance in higher education. The exclusive ranking identifies colleges that achieve an A+ grade in at least one of four core categories-Career Outcomes, Completion Rates, Support Services, or Cost Effectiveness-while maintaining A or A- grades in at least two others.
This rigorous methodology, which goes beyond single-dimensional…
BlueDocs Unveils Revolutionary AI Global Search Feature, Transforming How Organi …
BlueDocs announces AI Global Search, a revolutionary feature that unifies knowledge discovery across multiple enterprise platforms. This advanced internal documentation software capability integrates with Google Workspace and Microsoft 365, with additional platforms planned, enabling organizations to search all their knowledge assets from a single interface while maintaining native platform access and enterprise-grade security.
San Francisco, USA - Septemper 8, 2025 - BlueDocs [https://bluedocs.io/], the leading all-in-one internal documentation software [https://bluedocs.io/internal-documentation-software] platform,…
Rita Hayworth Revealed: Quinn Lemley Brings Hollywood's Goddess To Life In Song
Beneath the sparkle of stardom lies a story of passion, heartbreak, and grit - captured in a glamorous big-band tribute now available worldwide.
Fresh off her win as Best Female Vocalist (NYC) at the 2025 Broadway World Awards and a Josie Award nomination for Best Jazz Vocalist, Quinn Lemley announces the release of her new album, Rita Hayworth Revealed , now available worldwide.
Backed by an 11-piece orchestra, Lemley reimagines the iconic…
More Releases for NF1
Neurofibromatosis Market Dynamics Indicate Upward Trajectory Through 2032, Repor …
DelveInsight's "Neurofibromatosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Neurofibromatosis, historical and forecasted epidemiology as well as the Neurofibromatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Neurofibromatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurofibromatosis Market Forecast
https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Neurofibromatosis…
Strong Growth Ahead: Neurofibromatosis Type 1 Market Size To Grow At Arecord 9.6 …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Neurofibromatosis Type 1 Market Size Expected to Be by 2034?
In recent times, the growth of the neurofibromatosis type 1 (NF1) market size has been robust. The market is predicted to escalate from $8.06 billion in 2024 to $8.86 billion in 2025, exhibiting a compound annual growth rate…
Neurofibromatosis Type 1 Pipeline: Emerging Targeted Therapies and Gene-Based Ap …
The treatment landscape for Neurofibromatosis Type 1 (NF1), a rare genetic disorder characterized by nerve sheath tumors, skin changes, and other systemic complications, is undergoing a pivotal transformation. Historically limited to symptomatic and surgical management, recent advances are driving the development of disease-modifying therapies that target the underlying genetic and molecular mechanisms. With no curative treatments available, there is a growing focus on MEK inhibitors, RAS/MAPK pathway modulators, and gene…
In-Depth Analysis of the Neurofibromatosis Type 1 Market: Growth Opportunities, …
What industry-specific factors are fueling the growth of the neurofibromatosis type 1 market?
The rising occurrence of spontaneous (de novo) mutations is expected to boost the growth of the neurofibromatosis type 1 (NF1) market. Spontaneous mutations occur due to errors in DNA replication or environmental factors, rather than being inherited. In NF1, the high mutation rate in the NF1 gene contributes to new cases, even without a family history. For example,…
The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 milli …
The ongoing NF1-PN drug development pipeline features additional MEK inhibitors, including Mirdametinib (SpringWorks Therapeutics), FCN-159 (Fosun Pharmaceutical), and PAS-004 (Pasithea Therapeutics). Additionally, HLX-1502 (Healx) is an emerging investigational therapy that provides a novel treatment approach for NF1 patients.
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new…
Simpli- Automation and Neuro Force One Announce Commencement of Pre-Clinical Tri …
Scottsdale, AZ - June 3, 2024 - Simpli- Automation and Neuro Force One (NF1) proudly announce the initiation of pre-clinical trials for Provectus Trademark , an innovative AI-powered olfactory sensor technology developed by Simpli- Automation. This collaborative endeavor represents a signicant leap forward in health monitoring, diagnostics, and human performance enhancement.
Provectus Trademark , spearheaded by Simpli- Automation, aims to enhance health, wellness, remediation and human performance by providing holistic analyses…
